[Panitumumab-treatment of metastatic colorectal cancer].
In the molecular target treatment strategy of metastatic colorectal cancer patients panitumumab represents a new class of drugs due to its fully human nature, and no need for premedication and loading dose. Panitumumab binds to epidermal growth factor receptor (EGFR) selectively. In registration pivotal studies the analysis of patient subgroups for KRAS status gives strong evidence for the important role of RAS oncogene: median progression-free survival was 16 weeks on panitumumab arm in KRAS wild-type patients (8 weeks in best supportive care), while in KRAS mutant patients panitumumab showed no efficacy, however adverse events were more frequent and severe. According to SmPC, panitumumab is indicated as monotherapy for the treatment of patients with EGFR expressing metastatic colorectal carcinoma with non-mutated (wild-type) KRAS after failure of fluoropyrimidine-, oxaliplatin- , and irinotecan-containing chemotherapy regimens. Adverse events are similar as with other EGFR inhibitors: skin symptoms (rash), lung infiltrates, diarrhoea, ion abnormalities of renal origin. The drug was formerly available via named patient reimbursement, and now is financed by diagnosis-related group (DRG) system.
Pikó
Béla
B
Békés Megyei Képviselotestület Pándy Kálmán Kórháza Megyei Onkológiai Központ 5700 Gyula Semmelweis u. 1. piko_bhome@freemail.hu
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D003967:Diarrhea / Q000139:chemically induced; D018572:Disease-Free Survival; D066246:ErbB Receptors / Q000187:drug effects* / Q000378:metabolism; D011905:Genes, ras / Q000187:drug effects; D006801:Humans; D006996:Hypocalcemia / Q000139:chemically induced; D008168:Lung / Q000187:drug effects; D008171:Lung Diseases / Q000139:chemically induced; D008274:Magnesium / Q000097:blood; D000077544:Panitumumab; D012867:Skin / Q000187:drug effects; D012871:Skin Diseases / Q000139:chemically induced; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000077544:Panitumumab; D066246:ErbB Receptors; D008274:Magnesium